abs158.txt	checkpoint	immunotherapy	uses	highly	selective	humanized	monoclonal	antibodiesagainst	checkpoint	signals	such	as	programmed	cell	death	receptor	(pd-1)	andprogrammed	cell	death	ligand	(pd-l1)		by	blocking	these	receptors	and	signals	the	immune	system	can	be	reactivated	to	fight	the	tumor		immunotherapy	foradvanced	non-small	cell	lung	cancer	(nsclc)	has	resulted	in	a	new	paradigm	oftreatment	options	resulting	in	improved	survival	and	response	rates	and	has	aless	severe	yet	unique	toxicity	profile	when	compared	to	chemotherapy		pd-1inhibitors		nivolumab	and	pembrolizumab		and	pd-l1	inhibitor		atezolizumab		arecurrently	approved	by	regulatory	authorities	for	the	treatment	of	advanced	nsclc	this	article	provides	a	detailed	review	of	these	newer	agents		their	mechanism	ofaction		side-effect	profile		therapeutic	indications	and	current	evidencesupporting	their	use	in	the	management	of	nsclc	
